Search all trials

Find therapies in clinical trials near you – page 6

Search by disease and location to discover available clinical trials matching your criteria. Updated every day from authoritative EU registries.

recruiting: 3 961
countries: 28
conditions: 2 103

3 961 trials recruiting28 European countries2 103 conditions coveredUpdated today

Quick filters

Squamous cell carcinoma of head and neck+7

Not recruiting

Registered drugNo placebo

Study on the Safety and Effects of Durvalumab and Tremelimumab with Radiotherapy for Patients with Metastatic Squamous Cell Carcinoma

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Durvalumab

Contact Research Centre

Squamous cell carcinoma of head and neck

Not recruiting

InvestigationalNo placebo

Study of Tislelizumab, Surzebiclimab, and LBL-007 for Patients with Recurrent or Metastatic Head and Neck Cancer

InvestigationalNo placebo

France

Participants:18–64 years · 65+ years
Substances:Lbl-007

Contact Research Centre

Squamous cell carcinoma of head and neck

Not recruiting

Registered drugNo placebo

Study of ALE.C04 and Pembrolizumab for Adults with Recurrent or Metastatic Head and Neck Cancer

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Ale.c04

Contact Research Centre

Squamous cell carcinoma of head and neck+2

Not recruiting

InvestigationalNo placebo

Study of BGB-A425, LBL-007, and Tislelizumab for Patients with Advanced Head and Neck Cancer, Lung Cancer, or Kidney Cancer

InvestigationalNo placebo

France

Participants:18–64 years · 65+ years
Substances:Lbl-007

Contact Research Centre

Squamous cell carcinoma of head and neck

Not recruiting

Registered drugNo placebo

Study of Pembrolizumab and Cisplatin for Patients with Stage III-IVA Resectable Head and Neck Cancer

Registered drugNo placebo

Austria

Participants:18–64 years · 65+ years
Substances:Cisplatin

Contact Research Centre

Squamous cell carcinoma of head and neck

Not recruiting

Investigational

Study on Radiotherapy with Xevinapant or Placebo for Older Patients with Advanced Head and Neck Cancer

Investigational

Belgium

Participants:65+ years
Substances:Xevinapant

Contact Research Centre

Squamous cell carcinoma of head and neck+1

Not recruiting

Registered drugNo placebo

Study of IO102-IO103 and Pembrolizumab for Patients with Resectable Melanoma and Head and Neck Squamous Cell Carcinoma

Registered drugNo placebo

Denmark

Participants:18–64 years · 65+ years
Substances:Io103 Acetate

Contact Research Centre

Squamous cell carcinoma of head and neck

Not recruiting

InvestigationalNo placebo

Study of Retifanlimab, INCAGN02385, and INCAGN02390 for First-Line Treatment in Patients with PD-L1 Positive Recurrent/Metastatic Head and Neck Cancer

InvestigationalNo placebo

France

Participants:18–64 years · 65+ years
Substances:Retifanlimab

Contact Research Centre

Find therapies in clinical trials near you – page 6

68 trials match your criteria

Squamous cell carcinoma of head and neck+7

Study on the Safety and Effects of Durvalumab and Tremelimumab with Radiotherapy for Patients with Metastatic Squamous Cell Carcinoma

Squamous cell carcinoma of head and neck

Study of Tislelizumab, Surzebiclimab, and LBL-007 for Patients with Recurrent or Metastatic Head and Neck Cancer

Squamous cell carcinoma of head and neck

Study of ALE.C04 and Pembrolizumab for Adults with Recurrent or Metastatic Head and Neck Cancer

Squamous cell carcinoma of head and neck+2

Study of BGB-A425, LBL-007, and Tislelizumab for Patients with Advanced Head and Neck Cancer, Lung Cancer, or Kidney Cancer

Squamous cell carcinoma of head and neck

Study of Pembrolizumab and Cisplatin for Patients with Stage III-IVA Resectable Head and Neck Cancer

Squamous cell carcinoma of head and neck

Study on Radiotherapy with Xevinapant or Placebo for Older Patients with Advanced Head and Neck Cancer

Squamous cell carcinoma of head and neck+1

Study of IO102-IO103 and Pembrolizumab for Patients with Resectable Melanoma and Head and Neck Squamous Cell Carcinoma

Squamous cell carcinoma of head and neck

Study of Retifanlimab, INCAGN02385, and INCAGN02390 for First-Line Treatment in Patients with PD-L1 Positive Recurrent/Metastatic Head and Neck Cancer

Explore other searches

Vaccine trials

Paediatric trials · ages 0–17

Healthy volunteers

Helpful resources

How applying through us works

What happens after you apply

Guides for patients and volunteers

Search filters

Prefer not to search? Our Concierge searches the trials for you.